Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Eur J Clin Invest. 2019 Sep 30;49(11):e13169. doi: 10.1111/eci.13169

Table 2.

Adherence to individual TIDieR items

Sample 1
% reporting among sample of placebo-controlled trials published in top journals (n=94)
Sample 2
% reporting among sample of placebo-controlled trials (n=100)
Sample 3
% reporting among placebo-controlled trials that reported using TIDieR (n=6)
Mentioned using TIDieR 0 0 100
TIDieR item
 Brief name 100 98 100
 Why 8.5 7 16.7
 What (materials) 68.1 60 33.3
 What (procedures) 92.6 65 100
 Who provided 45.7 59 83.3
 How 68.1 82 83.3
 Where 68.1 63 100
 When and how much 97.9 89 100
 Tailoring 59.6 15 50
 Modifications 25.5 4 33.3
 How well (planned adherence/fidelity assessment) 55.3 20 33.3
 How well (actual adherence/fidelity) 54.3 12 33.3
Addressed all TIDieR items 0 0 0
Mean number of items addressed 7.5 (SD 1.8) 5.7 (SD 1.7) 7.7 (SD 2.5)

SD= standard deviation